Choreo LLC Makes New Investment in Gossamer Bio, Inc. (NASDAQ:GOSS)

Choreo LLC bought a new position in Gossamer Bio, Inc. (NASDAQ:GOSS) in the second quarter, according to its most recent disclosure with the SEC. The firm bought 48,111 shares of the company’s stock, valued at approximately $46,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Sequoia Financial Advisors LLC increased its stake in shares of Gossamer Bio by 27.2% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 93,500 shares of the company’s stock worth $84,000 after acquiring an additional 20,000 shares during the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of Gossamer Bio in the 1st quarter worth $29,000. SG Americas Securities LLC acquired a new stake in shares of Gossamer Bio in the 1st quarter worth $34,000. Financial Advocates Investment Management increased its position in shares of Gossamer Bio by 57.5% during the 2nd quarter. Financial Advocates Investment Management now owns 106,850 shares of the company’s stock worth $96,000 after purchasing an additional 39,000 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Gossamer Bio by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 11,763,784 shares of the company’s stock worth $13,881,000 after purchasing an additional 128,150 shares during the last quarter. 81.23% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

GOSS has been the subject of a number of recent analyst reports. The Goldman Sachs Group reissued a “buy” rating and set a $8.00 price objective on shares of Gossamer Bio in a research report on Monday, June 17th. Wedbush reissued an “outperform” rating and set a $4.00 price objective on shares of Gossamer Bio in a research report on Tuesday, August 13th. Oppenheimer initiated coverage on Gossamer Bio in a research report on Tuesday, June 25th. They set an “outperform” rating and a $9.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Gossamer Bio in a research report on Tuesday. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Gossamer Bio presently has an average rating of “Buy” and a consensus price target of $9.20.

Gossamer Bio Stock Performance

NASDAQ GOSS opened at $1.05 on Friday. The company has a market cap of $237.53 million, a P/E ratio of -0.99 and a beta of 1.95. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.21 and a quick ratio of 8.21. The stock has a 50-day moving average of $0.93 and a two-hundred day moving average of $0.91. Gossamer Bio, Inc. has a 1-year low of $0.45 and a 1-year high of $1.60.

Gossamer Bio (NASDAQ:GOSS) last released its earnings results on Monday, August 12th. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.01). The business had revenue of $95.84 million during the quarter, compared to the consensus estimate of $160.00 million. As a group, analysts anticipate that Gossamer Bio, Inc. will post -0.33 EPS for the current year.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.